Compare Dow Inc (DOW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Dow Inc trades at $30.6 (market cap $22.58B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Dow Inc pays a 4.48% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Dow Inc nearer its low. Which is the better fit depends on your goals.
| DOW | XBI | |
|---|---|---|
Market Cap | $22.58B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $41.87 | $164.28 |
52-Week Low | $20.65 | $86.92 |
Enterprise Value | $38.27B | — |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.64, up 0.2% with a bullish technical signal and recent earnings beats. The company shows declining revenue trends from $56.9B in 2022 to $40.0B in 2025, with negative net income margins. Analyst consensus is mixed with 33% buy ratings and a $35.11 price target, representing 15% upside. Recent dividend payment of $0.35 provides income support amid challenging fundamentals.
While technical indicators suggest near-term strength, fundamental challenges persist with negative profitability and declining cash flow. The stock offers potential upside to analyst targets but faces execution risks in a competitive chemical sector. Dividend yield provides some cushion, but investors need sustained operational improvement for meaningful long-term returns.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
